Efficacy Study of Yi-Zhi-An-Shen Granules For Older Adults With Amnestic Mild Cognitive Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-21

Study Completion Date

2019-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to investigate the safety and efficacy of Yi-Zhi-An-Shen Granules in participants with amnestic mild cognitive impairment (aMCI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease

NCT04780399

Alzheimer Disease Yangxue Qingnao Pills Randomized

UNKNOWN PHASE2

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

NCT01569516

Alzheimer's Disease

UNKNOWN PHASE2

Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease

NCT03790982

Alzheimer's Disease

UNKNOWN PHASE2

Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment

NCT02982603

Mild Cognitive Impairment Herbal Medicine Allergy

COMPLETED PHASE4

Efficacy and Safety of 1612 Capsules in aMnestic Mild Cognitive Impairment

NCT02982642

Mild Cognitive Impairment

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators performed a randomized, placebo-controlled, double-blind study on evaluating effect of Yi-Zhi-An-Shen Granules on cognition, sleep quality, and gut microbiome of older adults with amnestic mild cognitive impairment (aMCI). The investigators plan to involve 80 cases for observation in 2 years (40 cases for each group), expecting that cognition and sleep quality of aMCI patients can be improved by Yi-Zhi-An-Shen Granules versus placebo, and discussing the differences between individuals with aMCI and ones with normal cognition, also investigating whether this Chinese medicine compound can regulate gut microbiome of older individuals with aMCI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A randomized, double-blind, placebo-controlled study.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Yi-Zhi-An-Shen

Yi-Zhi-An-Shen Granules given three times every day for 16 weeks.

Group Type EXPERIMENTAL

Yi-Zhi-An-Shen

Intervention Type DRUG

Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.

Placebo

Placebo given three times every day for 16 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo granules 5g given three times a day for up to 16 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Yi-Zhi-An-Shen

Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.

Intervention Type DRUG

Placebo

Placebo granules 5g given three times a day for up to 16 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has assigned informed consent to participate in the study and continues to give willing consent for participation
* Age from 60 to 85 years with a diagnosis of aMCI
* Educational level of at least 6 years
* Availability of a "study partner" who can assist in completing rating scales for the duration of the study
* Cognitive complaints reported by the subject and confirmed by the "study partner"
* Clinical Dementia Rating (CDR) global score of 0.5, and memory item score of 0.5
* Mini-mental state examination (MMSE) score of 24-30
* Diagnostic and Statistical Manual of Mental Disorders, Version 5 (DSM-V) criteria of dementia not fulfilled

Exclusion Criteria

* Has been previously enrolled in this study and received the investigational product
* Has received an investigational product within 30 days prior to screening
* Has received disease-modifying therapy
* Has a known allergy to the study drug or any of its constituents
* Has a history of alcohol abuse or alcohol dependency in the 3 years prior to study entry, or is an alcoholic or drug addict, as determined by the investigator
* Has ongoing clinically significant (as judged by the investigator), metabolic or any other disease that could currently cause impaired memory (e.g., untreated thyroid disease, vitamin or other nutritional deficiencies, chronic kidney, or liver disease)
* Memory impairment that can be attributed to a disease or condition other than an early phase neurodegenerative syndrome
* Has a parkinsonian movement disorder
* Use of psychoactive medications that would affect the subject's ability to reliably perform neurocognitive testing or create uncertainty in distinguishing between the effects of the psychoactive medication and the subject's underlying cognitive impairment (e.g., benzodiazepines, sedatives, antipsychotics)
* History of major recurrent depressive disorder (DSM-V) within the last 5 years prior to screening
* Has a brain tumor or other intracranial lesion, a disturbance of cerebral spinal fluid circulation (e.g., normal pressure hydrocephalus), and/or a significant history of head trauma or brain surgery
* Has signs of major cerebrovascular disease, with score of modified Hachinski Ischemia Score (mHIS) at more than 4, or as verified by medical history and/or brain MRI or CT
* Has severe visual or hearing impairments that cannot cooperate with examinations
* Has severe digestive system diseases
* Has received antibiotics within 60 days prior to screening

Minimum Eligible Age

60 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes